Whole MBC population (n = 244) | BM population (n = 86) | |||
---|---|---|---|---|
Parameter | Median OS in months (95 CI%) | P-value | Median OS in months (95 CI%) | P-value |
Initial characteristics | ||||
Tumor biology group HER2+ HR+ HER2+ HR- HER2- HR+ Triple negative | 28.6 (16.5 – NC) 31.6 (20.2–34.5) 12.4 (10.4–22.5) 6.3 (4.5–10.4) | < 0.001 | 14.4 (8.1–20.1) 8.7 (2.6–20.2) 9.7 (2.6–16.2) 4.6 (2.0–8.5) | 0.0598 |
PR status Negative Positive | 12.5 (10.6–17.8) 21.7 (16.2–35.6) | 0.044 | 8.1 (4.6–10.4) 16.2 (9.7–21.7) | 0.119 |
HER2 status Negative Positive | 10.4 (8.4–12.4) 28.7 (20.1–33.9) | < 0.001 | 6.4 (4.2–10.0) 12.1 (8.1–19.1) | 0.037 |
Histological grade (SBR) 1 or 2 3 | 20.9 (15.1–31.6) 11.1 (9.5–15.0) | 0.012 | 10.4 (6.4–20.6) 8.1 (4.2–10.4) | 0.117 |
Metastatic status at BC diagnosis M0 M1 | 13.6 (10.5–16.5) 27.2 (13.7–32.1) | 0.016 | 8.5 (4.7–10.0) 11.6 (4.2–20.9) | 0.056 |
Adjuvant or néoadjuvant CT No Yes | 20.7 (16.8–31.6) 12.5 (10.3–15.5) | 0.009 | 11.6 (8.4–20.3) 6.8 (3.3–10.3) | 0.007 |
Characteristics at the time of the serum sample | ||||
ECOG status Score 0 Score 1 Score 2 Score 3 | 34.5 (20.9–63.6) 16.5 (12.1–22.5) 6.8 (3.8–16.8) 2.0 (1.4–2.6) | < 0.001 | 14.4 (10.0 – NC) 12.1 (8.4–19.1) 8.5 (1.5–17.6) 2.0 (1.2–4.6) | < 0.001 |
Number of lines of CT 0 line 1 or 2 line(s) > 2 lines | 17.8 (15.0–27.8) 20.9 (16.3–32.0) 6.4 (4.6–10.4) | < 0.001 | 8.5 (4.7–17.6) 12.4 (8.4–20.3) 4.6 (2.2–9.7) | 0.007 |
Number of metastatic sites 1–3 ≥4 | 30.7 (19.1–59.2) 11.7 (9.9–15.0) | < 0.001 | 10.3 (5.6–19.1) 9.7 (4.7–12.1) | 0.309 |
Location of metastatic sites Bone and/or subcutaneous only Visceral | 63.6 (16.5 – NC) 14.4 (11.4–19.1) | 0.0016 | NC 9.7 (5.6–10.8) | 0.843 |
Brain metastases Absent Present | 30.4 (16.8–34.5) 9.7 (5.6–10.8) | < 0.001 | - - | – |
Liver metastases Absent Present | 28.7 (14.9–36.8) 12.4 (10.6–17.2) | < 0.001 | 6.8 (3.8–10.4) 9.8 (4.9–13.6) | 0.377 |
Subcutaneous metastases Absent Present | 19.2 (13.7–22.6) 10.4 (4.6–15.2) | 0.0034 | 10.0 (8.1–13.6) 4.7 (1.4–9.8) | 0.011 |
Metastases of other sites Absent Present | 20.9 (16.2–30.7) 10.6 (6.4–12.5) | < 0.001 | 10.0 (8.1–15.5) 5.3 (2.8–11.6) | 0.876 |
Serum albumin level Normal Low | 14.4 (11.1–19.4) 1.6 (1.1–2.4) | < 0.001 | 10.0 (6.8–12.4) 1.4 (0.7–2.6) | < 0.001 |
Serum CEA Normal Elevated | 20.1 (15.5–28.6) 11.1 (8.7–13.6) | 0.003 | 10.0 (4.7–15.5) 9.7 (3.3–12.1) | 0.483 |
Serum CA 15–3 Normal Elevated | 28.7 (19.4–59.2) 11.4 (9.7–14.4) | < 0.001 | 10.4 (6.8–20.1) 8.5 (4.0–10.4) | 0.096 |
Serum HER2 ECD (cut-off 15 ng/mL) Normal Elevated | 21.7 (15.2–31.6 11.4 (8.9–14.4) | < 0.001 | 10.3 (4.7–21.7) 8.7 (4.6–12.1) | 0.085 |
Serum Tau (cut-off 0.74 pg/mL*) Normal Elevated | 33.2 (19.2–42.8) 12.4 (10.6–16.3) | 0.007 | 12.1 (6.8–28.6) 8.5 (4.6–10.4) | 0.060 |
Serum Tau (cut-off 1.24 pg/mL**) Normal Elevated | 23.0 (15.0–33.2) 11.3 (9.5–16.3) | 0.0011 | 10.3 (4.6–12.4) 8.7 (4.9–12.4) | 0.942 |
Serum Tau (cut-off 3.17 pg/mL***) Normal Elevated | 20.6 (16.2–30.4) 9.5 (4.9–10.8) | < 0.001 | 10.3 (5.3–13.6) 8.7 (2.6–10.8) | 0.389 |